nilotinib

Tasigna, also known as nilotinib, is an oral chemotherapy medication produced by Novartis. It was granted approval by the U.S. Food and Drug Administration in 2007. Physicians commonly prescribe this drug to address Philadelphia chromosome-positive chronic myeloid leukemia, a specific form of blood cancer.

The estimated rate of event-free survival (EFS) at 12 months, as determined by the K-M method, was 96.3% (95% CI, 76.5-99.5). This rate remained unchanged until the end of the study. In the non-disease (ND) cohort, 21 patients (84.0%) achieved complete cytogenetic response (CCyR) by cycle 12 and maintained this response until the end of the study. The median time to first CCyR was 5.6 months (95% CI, 5.5-5.6).

Asciminib (Scemblix) is the most recent medication approved by the FDA in October 2021 for the treatment of Chronic Myeloid Leukemia (CML). It is specifically designed for individuals with CML who have shown resistance or intolerance to two prior TKIs or possess the T315I mutation.

To ensure the effectiveness of TKIs in treating chronic myeloid leukaemia (CML) and minimize side effects, it is advised to avoid consuming grapefruit, grapefruit juice, pomegranate, Seville oranges, or any Seville orange juice. These fruits contain chemicals that can interfere with the proper functioning of TKIs. However, other types of oranges and orange juice are still safe to consume.

Tasigna may also lead to heart-related side effects, including edema (fluid retention) and swelling around the heart. It can also cause blockages in the heart or arteries, potentially resulting in angina or a heart attack. Additionally, Tasigna may cause an abnormal heartbeat due to electrolyte imbalance or tumor lysis syndrome, which are other known side effects of the medication.

Nilotinib is a specific type of cancer medication known as a tyrosine kinase inhibitor (TKI). It works by targeting and inhibiting the activity of a protein called BCR-ABL, which is responsible for stimulating the growth of cancer cells.

During your treatment with TASIGNA, it is important to avoid consuming grapefruit, grapefruit juice, and any supplements that contain grapefruit extract. This is because these food and grapefruit products can increase the levels of TASIGNA in your body. Additionally, it is advised to refrain from taking any other medications or supplements that may also cause QTc prolongation while taking TASIGNA.

Nilotinib, marketed globally as Tasigna by Novartis, is a pharmaceutical prescribed for the treatment of chronic myelogenous leukemia (CML) associated with the Philadelphia chromosome.

The regular price for 30 capsules of 200MG Tasigna is $9,211.41, but with the NowPatient Rx Advantage Card, you can purchase it for $5,223.13, saving 43%. We advise comparing prices even if Medicare or your insurance covers this medication.

Nilotinib is a drug that inhibits transduction and targets BCR-ABL, c-kit, and PDGF. It has potential for treating various leukemias, including chronic myeloid leukemia (CML), which is caused by the BCR-ABL oncogene. Nilotinib works by inhibiting the tyrosine kinase activity of the BCR-ABL protein.

The ENESTnd study found that nilotinib had higher and faster response rates compared to imatinib in newly diagnosed chronic myeloid leukemia patients. Additionally, nilotinib was associated with a lower risk of progression to accelerated phase/blast crisis.

The six-year overall survival and progression-free survival rates were 96%, with one death occurring after progression to blast phase. At the six-year mark, 75% of the patients were still taking nilotinib. The cumulative incidence of major molecular response was 98%, with only one patient experiencing a confirmed loss of major molecular response.

The most common side effects of imatinib treatment include nausea, vomiting, diarrhea, fluid retention, fatigue, and muscle spasms. On the other hand, nilotinib treatment often leads to an increase in cardiovascular events, specifically QT prolongation, as well as a skin rash.

Imatinib (Glivec) is the most frequently prescribed drug for CML. However, your doctor may recommend alternative TKIs like dasatanib (Sprycel) or nilotinib (Tasigna). The majority of individuals respond positively to this treatment, and CML can be effectively managed for extended periods of time.

In 2001, the treatment of chronic myeloid leukemia (CML) was revolutionized by the introduction of Imatinib, also known as “Gleevec” or “Glivec.” This tyrosine kinase inhibitor was hailed as a “magical bullet” for its remarkable effectiveness.

Imatinib was discontinued for various reasons, including adverse events (n=18), patients requesting to discontinue due to cost (n=14), patients wanting to become pregnant (n=3), and long undetectable residual disease (n=8).

Tasigna, an oral targeted drug therapy, falls under the category of tyrosine kinase inhibitors (TKIs). Unlike traditional chemotherapy, it is not classified as “chemo” treatment, but it effectively eliminates cancer cells. These targeted drug therapies specifically target and attack certain types of cancer cells, minimizing harm to healthy cells.

Imatinib (Gleevec) has transformed chronic myelogenous leukemia (CML) from a previously fatal blood cancer into a manageable condition, enabling individuals to live a nearly normal lifespan.

Tasigna (nilotinib), Gleevec (imatinib), and Sprycel (dasatinib) are three medications. Tasigna does not have a lower-cost generic available, while Gleevec has a lower-cost generic option. Sprycel also does not have a lower-cost generic available.

Possible drug interactions with this medication include antacids, elacestrant, flibanserin, H2 blockers like cimetidine or famotidine, and proton pump inhibitors like omeprazole. It is important to note that other medications can also impact the elimination of nilotinib from the body, potentially affecting its effectiveness.

In a study testing increasing doses of nilotinib on patients with imatinib-resistant chronic myeloid leukemia (CML), a notable number of patients experienced positive responses in terms of blood cell counts and genetic abnormalities in all stages of CML.

If you and your healthcare provider determine that you can discontinue TASIGNA and attempt TFR, you may experience an increase in musculoskeletal symptoms compared to before you stopped treatment. These symptoms may consist of muscle pain as well as pain in the arms and legs.

Based on the information provided in MedsPaL, it is expected that starting from July 2023, a generic company will have the opportunity to sell generic nilotinib in 108 LMICs and 22 high-income countries. It is important to note that this availability is not affected by any license agreement, as Novartis does not hold any valid patents related to nilotinib in these countries.

Symptoms include nausea, diarrhea, rash, cough, headache, constipation, tiredness, and muscle and joint pain.

During your treatment with TASIGNA, it is important to avoid consuming grapefruit, grapefruit juice, and any supplements that contain grapefruit extract. This is because these food and grapefruit products can increase the levels of TASIGNA in your body. Additionally, it is advised to refrain from taking any other medications or supplements that may also cause QTc prolongation while taking TASIGNA.

Tasigna may lead to hair loss or thinning, although it is not a frequently reported side effect in clinical trials. It is important to note that other cancer therapies may also result in hair loss.

Tasigna can cause tumor lysis syndrome, which is characterized by rapid breakdown of cancer cells. This condition can result in kidney failure and irregular heartbeat.

During Tasigna treatment, it is possible to experience either weight loss or weight gain. Clinical studies have shown that approximately 1% to 10% of individuals who took Tasigna experienced changes in their weight. If you notice a sudden and unexplained increase in weight, it could be a sign of edema, which is the retention of fluid in the body. Other symptoms of edema include swelling and shortness of breath.

For optimal results, it is recommended to consume this medication when your stomach is empty. It is advised to take it at least one hour before or two hours after a meal. Take the capsule with a full glass of water without breaking or chewing it. In case you have difficulty swallowing the capsule, you may open it and mix the contents with one teaspoon of applesauce. However, it is important not to mix Tasigna® with any other type of food.

If you are currently being treated for high blood pressure, it is important to inform your doctor about it as Nilotinib may potentially increase your blood pressure.

Tasigna may occasionally lead to liver issues, including abnormal liver function, hepatitis, and liver damage. Clinical trials have shown that abnormal liver function is a common side effect of Tasigna, especially in children. However, hepatitis and liver damage are less common occurrences.